

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/594,851
				Filing Date	April 1, 2005 (Int'l.)
				First Named Inventor	Tania KASTELIC
				Art Unit	1636
				Examiner Name	C. Hibbert
Sheet	1	of	2	Attorney Docket Number	608352000101

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1.	US-2009/0068654-A1	10-06-2009	Kastelic et al.	
	2.	US-7,598,079-B2	11-18-2004	Kastelic et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	3.	GB-9828707.1	02-17-1999	Novation Pharmaceuticals, Inc.		
	4.	GB-9828710.5	02-17-1999	Novation Pharmaceuticals, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/594,851
				Filing Date	April 1, 2005 (Int'l.)
				First Named Inventor	Tania KASTELIC
				Art Unit	1636
				Examiner Name	C. Hibbert
Sheet	2	of	2	Attorney Docket Number	608352000101

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	5.	Al, L-S. et al. (October 15, 1999). "Post-Transcriptional Regulation of H-ferritin mRNA," <i>J. Biol. Chem.</i> 274(42):30209-30214.		
	6.	DALGLEISH, G. et al. (April 27, 2001). "mRNA Localization by a 145-Nucleotide Region of the c-fos 3'- Untranslated Region. Links to Translation But Not Stability," <i>J. Biol. Chem.</i> 276(17):13593-13599.		
	7.	International Search Report mailed June 6, 2000, for PCT Application No. PCT/CA99/01235 filed December 23, 1999, three pages.		
	8.	LEE, W.Y. et al. (October 27, 2000). "Cyclic Nucleotide Regulation of Na <sup>+</sup> /Glucose Cotransporter (SGLT1) mRNA Stability," <i>J. Biol. Chem.</i> 275(43):33998-34008.		
	9.	LUNDBERG, U. et al. (1990). "Cleavages in the 5' Region of the ompA and bla mRNA Control Stability: Studies with an <i>E. coli</i> Mutant Altering mRNA Stability and a Novel Endoribonuclease," <i>EMBO Journal</i> 9(9):2731-2741.		
	10.	Notice of Allowance mailed on May 28, 2009, for U.S. Patent Application No. 10/814,634, filed on April 1, 2004, 7 pages.		
	11.	SCHIAVONE, N. et al. (January 2000). "A Conserved AU-rich Element in the 3' Untranslated Region of bcl-2 mRNA is Endowed with a Destabilizing Function That Is Involved in bcl-2 Down-Regulation During Apoptosis," <i>FASEB J.</i> 14(1):174-184.		
	12.	STOECKLIN, G. et al. (June 2000). "Somatic mRNA Turnover Mutants Implicate Tristetraprolin in the Interleukin-3 mRNA Degradation Pathway," <i>Mol. Cell. Biol.</i> 20(11):3753-3763.		
	13.	Supplemental Notice of Allowability and Examiner Interview Summary mailed on June 15, 2009, for U.S. Patent Application No. 10/814,634, filed on April 1, 2004, 5 pages.		
	14.	THAMES, E.L. et al. (2000). "Role of mRNA Stability and Translation in the Expression of Cytochrome c Oxidase During Mouse Myoblast Differentiation: Instability of the mRNA for the Liver Isoform of Subunit VIa," <i>Biochem. J.</i> 351(1):133-142.		
	15.	VELDHUISEN, G. et al. (1988). "Transient Expression in Mammalian Cells of the Bacterial Reporter Gene Encoding Mercuric Reductase: Effects of Various Regulatory Elements," <i>Gene</i> 71:381-390.		
	16.	VEYRUNE, J. L. et al. (1995). "c-fos mRNA Instability Determinants Present within both the Coding and the 3' Non Coding Region Link the Degradation of this mRNA to its Translation," <i>Oncogene</i> 11:2127-2134, erratum, <i>Oncogene</i> 12:2479.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.